203 related articles for article (PubMed ID: 20425517)
1. Bone changes and fracture risk in individuals infected with HIV.
Warriner AH; Mugavero MJ
Curr Rheumatol Rep; 2010 Jun; 12(3):163-9. PubMed ID: 20425517
[TBL] [Abstract][Full Text] [Related]
2. HIV infection and bone disease.
Compston J
J Intern Med; 2016 Oct; 280(4):350-8. PubMed ID: 27272530
[TBL] [Abstract][Full Text] [Related]
3. Bone health in HIV infection.
Pollock E; Klotsas AE; Compston J; Gkrania-Klotsas E
Br Med Bull; 2009; 92():123-33. PubMed ID: 19875393
[TBL] [Abstract][Full Text] [Related]
4. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
[TBL] [Abstract][Full Text] [Related]
5. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
Lin D; Rieder MJ
Cochrane Database Syst Rev; 2007 Apr; (2):CD005645. PubMed ID: 17443607
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy.
Bunders MJ; Frinking O; Scherpbier HJ; van Arnhem LA; van Eck-Smit BL; Kuijpers TW; Zwinderman AH; Reiss P; Pajkrt D
Clin Infect Dis; 2013 Feb; 56(4):583-6. PubMed ID: 23097583
[TBL] [Abstract][Full Text] [Related]
7. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
8. HIV infection and bone disease: implications for an aging population.
Cotter AG; Mallon PW
Sex Health; 2011 Dec; 8(4):493-501. PubMed ID: 22127034
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for low bone mineral density in HIV-infected subjects.
Cotter AG; Mallon PW
Curr HIV/AIDS Rep; 2012 Jun; 9(2):148-59. PubMed ID: 22528765
[TBL] [Abstract][Full Text] [Related]
10. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
[TBL] [Abstract][Full Text] [Related]
11. Management of bone mineral density in HIV-infected patients.
Negredo E; Bonjoch A; Clotet B
Expert Opin Pharmacother; 2016; 17(6):845-52. PubMed ID: 26809940
[TBL] [Abstract][Full Text] [Related]
12. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
[TBL] [Abstract][Full Text] [Related]
13. [Multifactorial relations between HIV, HAART and bone metabolism].
Borderi M
Infez Med; 2006 Sep; 14(3):117-24. PubMed ID: 17127825
[TBL] [Abstract][Full Text] [Related]
14. HIV infection--a risk factor for osteoporosis.
Thomas J; Doherty SM
J Acquir Immune Defic Syndr; 2003 Jul; 33(3):281-91. PubMed ID: 12843738
[TBL] [Abstract][Full Text] [Related]
15. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
16. Bone loss in patients with HIV infection.
Paccou J; Viget N; Legrout-Gérot I; Yazdanpanah Y; Cortet B
Joint Bone Spine; 2009 Dec; 76(6):637-41. PubMed ID: 19945322
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
18. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
Mora S; Sala N; Bricalli D; Zuin G; Chiumello G; Viganò A
AIDS; 2001 Sep; 15(14):1823-9. PubMed ID: 11579244
[TBL] [Abstract][Full Text] [Related]
20. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
